When should cardiologists suspect anderson-fabry disease?

Fabiana I. Gambarin, Eliana Disabella, Jagat Narula, Marta Diegoli, Maurizia Grasso, Alessandra Serio, B. M E Valentina Favalli, Manuela Agozzino, Luigi Tavazzi, Alan G. Fraser, Eloisa Arbustini

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Anderson-Fabry disease is a lysosomal storage disorder caused by α-galactosidase defects and progressive intracellular accumulation of globotriaosylceramide. The disease can be specifically treated with enzyme replacement therapy. Hemizygous men and heterozygous women can develop cardiac disease. Whereas men experience the most severe clinical phenotype, clinical presentation in women varies from asymptomatic to severely symptomatic. The characteristic cardiac phenotype is left ventricular hypertrophy mimicking sarcomeric hypertrophic cardiomyopathy or hypertensive heart disease. Early or prehypertrophy cardiac involvement may escape detection, unless electrocardiographic clues are present. The cardiac markers that raise suspicion of Anderson-Fabry disease include a short PR interval without a δ wave and a prolonged QRS interval, supraventricular and ventricular arrhythmias, and concentric left ventricular hypertrophy. Extracardiac features include renal failure, corneal deposits, and nervous, gastrointestinal, and cutaneous manifestations. Useful family data include cardiac and extracardiac traits in relatives and absence of male-to-male transmission. Symptoms are subtle, and the interval between the onset of symptoms and diagnosis may be as long as 20 years. As such, the diagnosis is typically late. Endomyocardial biopsy shows optically empty myocytes on light microscopy and dense osmiophilic bodies constituted of globotriaosylceramide on electron microscopy. Alpha-galactosidase A activity is reduced in hemizygous men but not in heterozygous women. Genetic testing is the gold standard for the diagnosis. In conclusion, a correct and timely diagnosis offers the possibility of disease-specific treatment that leads to sustained clinical benefits for cardiac and noncardiac signs and symptoms.

Original languageEnglish
Pages (from-to)1492-1499
Number of pages8
JournalThe American Journal of Cardiology
Volume106
Issue number10
DOIs
Publication statusPublished - Nov 15 2010

Fingerprint

Fabry Disease
Left Ventricular Hypertrophy
Heart Diseases
Galactosidases
Enzyme Replacement Therapy
alpha-Galactosidase
Phenotype
Skin Manifestations
Hypertrophic Cardiomyopathy
Genetic Testing
Muscle Cells
Signs and Symptoms
Renal Insufficiency
Cardiac Arrhythmias
Microscopy
Electron Microscopy
Biopsy
Light
Cardiologists
globotriaosylceramide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

When should cardiologists suspect anderson-fabry disease? / Gambarin, Fabiana I.; Disabella, Eliana; Narula, Jagat; Diegoli, Marta; Grasso, Maurizia; Serio, Alessandra; Favalli, B. M E Valentina; Agozzino, Manuela; Tavazzi, Luigi; Fraser, Alan G.; Arbustini, Eloisa.

In: The American Journal of Cardiology, Vol. 106, No. 10, 15.11.2010, p. 1492-1499.

Research output: Contribution to journalArticle

Gambarin, Fabiana I. ; Disabella, Eliana ; Narula, Jagat ; Diegoli, Marta ; Grasso, Maurizia ; Serio, Alessandra ; Favalli, B. M E Valentina ; Agozzino, Manuela ; Tavazzi, Luigi ; Fraser, Alan G. ; Arbustini, Eloisa. / When should cardiologists suspect anderson-fabry disease?. In: The American Journal of Cardiology. 2010 ; Vol. 106, No. 10. pp. 1492-1499.
@article{d693954fc03a46cd9c75e0ab68ff7e29,
title = "When should cardiologists suspect anderson-fabry disease?",
abstract = "Anderson-Fabry disease is a lysosomal storage disorder caused by α-galactosidase defects and progressive intracellular accumulation of globotriaosylceramide. The disease can be specifically treated with enzyme replacement therapy. Hemizygous men and heterozygous women can develop cardiac disease. Whereas men experience the most severe clinical phenotype, clinical presentation in women varies from asymptomatic to severely symptomatic. The characteristic cardiac phenotype is left ventricular hypertrophy mimicking sarcomeric hypertrophic cardiomyopathy or hypertensive heart disease. Early or prehypertrophy cardiac involvement may escape detection, unless electrocardiographic clues are present. The cardiac markers that raise suspicion of Anderson-Fabry disease include a short PR interval without a δ wave and a prolonged QRS interval, supraventricular and ventricular arrhythmias, and concentric left ventricular hypertrophy. Extracardiac features include renal failure, corneal deposits, and nervous, gastrointestinal, and cutaneous manifestations. Useful family data include cardiac and extracardiac traits in relatives and absence of male-to-male transmission. Symptoms are subtle, and the interval between the onset of symptoms and diagnosis may be as long as 20 years. As such, the diagnosis is typically late. Endomyocardial biopsy shows optically empty myocytes on light microscopy and dense osmiophilic bodies constituted of globotriaosylceramide on electron microscopy. Alpha-galactosidase A activity is reduced in hemizygous men but not in heterozygous women. Genetic testing is the gold standard for the diagnosis. In conclusion, a correct and timely diagnosis offers the possibility of disease-specific treatment that leads to sustained clinical benefits for cardiac and noncardiac signs and symptoms.",
author = "Gambarin, {Fabiana I.} and Eliana Disabella and Jagat Narula and Marta Diegoli and Maurizia Grasso and Alessandra Serio and Favalli, {B. M E Valentina} and Manuela Agozzino and Luigi Tavazzi and Fraser, {Alan G.} and Eloisa Arbustini",
year = "2010",
month = "11",
day = "15",
doi = "10.1016/j.amjcard.2010.07.016",
language = "English",
volume = "106",
pages = "1492--1499",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - When should cardiologists suspect anderson-fabry disease?

AU - Gambarin, Fabiana I.

AU - Disabella, Eliana

AU - Narula, Jagat

AU - Diegoli, Marta

AU - Grasso, Maurizia

AU - Serio, Alessandra

AU - Favalli, B. M E Valentina

AU - Agozzino, Manuela

AU - Tavazzi, Luigi

AU - Fraser, Alan G.

AU - Arbustini, Eloisa

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Anderson-Fabry disease is a lysosomal storage disorder caused by α-galactosidase defects and progressive intracellular accumulation of globotriaosylceramide. The disease can be specifically treated with enzyme replacement therapy. Hemizygous men and heterozygous women can develop cardiac disease. Whereas men experience the most severe clinical phenotype, clinical presentation in women varies from asymptomatic to severely symptomatic. The characteristic cardiac phenotype is left ventricular hypertrophy mimicking sarcomeric hypertrophic cardiomyopathy or hypertensive heart disease. Early or prehypertrophy cardiac involvement may escape detection, unless electrocardiographic clues are present. The cardiac markers that raise suspicion of Anderson-Fabry disease include a short PR interval without a δ wave and a prolonged QRS interval, supraventricular and ventricular arrhythmias, and concentric left ventricular hypertrophy. Extracardiac features include renal failure, corneal deposits, and nervous, gastrointestinal, and cutaneous manifestations. Useful family data include cardiac and extracardiac traits in relatives and absence of male-to-male transmission. Symptoms are subtle, and the interval between the onset of symptoms and diagnosis may be as long as 20 years. As such, the diagnosis is typically late. Endomyocardial biopsy shows optically empty myocytes on light microscopy and dense osmiophilic bodies constituted of globotriaosylceramide on electron microscopy. Alpha-galactosidase A activity is reduced in hemizygous men but not in heterozygous women. Genetic testing is the gold standard for the diagnosis. In conclusion, a correct and timely diagnosis offers the possibility of disease-specific treatment that leads to sustained clinical benefits for cardiac and noncardiac signs and symptoms.

AB - Anderson-Fabry disease is a lysosomal storage disorder caused by α-galactosidase defects and progressive intracellular accumulation of globotriaosylceramide. The disease can be specifically treated with enzyme replacement therapy. Hemizygous men and heterozygous women can develop cardiac disease. Whereas men experience the most severe clinical phenotype, clinical presentation in women varies from asymptomatic to severely symptomatic. The characteristic cardiac phenotype is left ventricular hypertrophy mimicking sarcomeric hypertrophic cardiomyopathy or hypertensive heart disease. Early or prehypertrophy cardiac involvement may escape detection, unless electrocardiographic clues are present. The cardiac markers that raise suspicion of Anderson-Fabry disease include a short PR interval without a δ wave and a prolonged QRS interval, supraventricular and ventricular arrhythmias, and concentric left ventricular hypertrophy. Extracardiac features include renal failure, corneal deposits, and nervous, gastrointestinal, and cutaneous manifestations. Useful family data include cardiac and extracardiac traits in relatives and absence of male-to-male transmission. Symptoms are subtle, and the interval between the onset of symptoms and diagnosis may be as long as 20 years. As such, the diagnosis is typically late. Endomyocardial biopsy shows optically empty myocytes on light microscopy and dense osmiophilic bodies constituted of globotriaosylceramide on electron microscopy. Alpha-galactosidase A activity is reduced in hemizygous men but not in heterozygous women. Genetic testing is the gold standard for the diagnosis. In conclusion, a correct and timely diagnosis offers the possibility of disease-specific treatment that leads to sustained clinical benefits for cardiac and noncardiac signs and symptoms.

UR - http://www.scopus.com/inward/record.url?scp=78149462203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149462203&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2010.07.016

DO - 10.1016/j.amjcard.2010.07.016

M3 - Article

C2 - 21059442

AN - SCOPUS:78149462203

VL - 106

SP - 1492

EP - 1499

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -